Table of Contents
ISRN Molecular Biology
Volume 2014 (2014), Article ID 190976, 5 pages
http://dx.doi.org/10.1155/2014/190976
Review Article

Recent Trends in Detection of Huntingtin and Preclinical Models of Huntington’s Disease

Department of Pharmaceutical Sciences, Butler University, 4600 Sunset Avenue, Indianapolis, IN 46208, USA

Received 11 February 2014; Accepted 20 March 2014; Published 14 May 2014

Academic Editors: M. Harata and T. Straub

Copyright © 2014 Neelima Mantha et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. S.-H. Li and X.-J. Li, “Huntingtin-protein interactions and the pathogenesis of Huntington's disease,” Trends in Genetics, vol. 20, no. 3, pp. 146–154, 2004. View at Publisher · View at Google Scholar · View at Scopus
  2. J.-H. J. Cha, “Transcriptional dysregulation in Huntington's disease,” Trends in Neurosciences, vol. 23, no. 9, pp. 387–392, 2000. View at Publisher · View at Google Scholar · View at Scopus
  3. A. Kazantsev, E. Preisinger, A. Dranovsky, D. Goldgaber, and D. Housman, “Insoluble detergent-resistant aggregates form between pathological and nonpathological lengths of polyglutamine in mammalian cells,” Proceedings of the National Academy of Sciences of the United States of America, vol. 96, no. 20, pp. 11404–11409, 1999. View at Publisher · View at Google Scholar · View at Scopus
  4. W. Liu, J. Goto, Y.-L. Wang, M. Murata, K. Wada, and I. Kanazawa, “Specific inhibition of Huntington's disease gene expression by siRNAs in cultured cells,” Proceedings of the Japan Academy B: Physical and Biological Sciences, vol. 79, no. 10, pp. 293–298, 2003. View at Google Scholar · View at Scopus
  5. C. T. Aiken, A. J. Tobin, and E. S. Schweitzer, “A cell-based screen for drugs to treat Huntington's disease,” Neurobiology of Disease, vol. 16, no. 3, pp. 546–555, 2004. View at Publisher · View at Google Scholar · View at Scopus
  6. E. L. Scotter, P. Narayan, M. Glass, and M. Dragunow, “High throughput quantification of mutant huntingtin aggregates,” Journal of Neuroscience Methods, vol. 171, no. 1, pp. 174–179, 2008. View at Publisher · View at Google Scholar · View at Scopus
  7. S. H. Li and X. J. Li, “In vitro expression systems for the Huntington protein,” in Neurogenetics, pp. 277–284, Springer, New York, NY, USA, 2003. View at Google Scholar
  8. W. Wang, W. Duan, S. Igarashi, H. Morita, M. Nakamura, and C. A. Ross, “Compounds blocking mutant huntingtin toxicity identified using a Huntington's disease neuronal cell model,” Neurobiology of Disease, vol. 20, no. 2, pp. 500–508, 2005. View at Publisher · View at Google Scholar · View at Scopus
  9. Y.-L. Wang, W. Liu, E. Wada, M. Murata, K. Wada, and I. Kanazawa, “Clinico-pathological rescue of a model mouse of Huntington's disease by siRNA,” Neuroscience Research, vol. 53, no. 3, pp. 241–249, 2005. View at Publisher · View at Google Scholar · View at Scopus
  10. Z. Qiu, F. Norflus, B. Singh et al., “Sp1 is up-regulated in cellular and transgenic models of huntington disease, and its reduction is neuroprotective,” The Journal of Biological Chemistry, vol. 281, no. 24, pp. 16672–16680, 2006. View at Publisher · View at Google Scholar · View at Scopus
  11. L. Massai, L. Petricca, L. Magnoni et al., “Development of an ELISA assay for the quantification of soluble huntingtin in human blood cells,” BMC Biochemistry, vol. 14, article 34, 2013. View at Google Scholar
  12. N. R. Franich, H. L. Fitzsimons, D. M. Fong, M. Klugmann, M. J. During, and D. Young, “AAV vector-mediated RNAi of mutant Huntingtin expression is neuroprotective in a novel genetic rat model of Huntington's disease,” Molecular Therapy, vol. 16, no. 5, pp. 947–956, 2008. View at Publisher · View at Google Scholar · View at Scopus
  13. D. W. Dodd, K. T. Gagnon, and D. R. Corey, “Digital quantitation of potential therapeutic target RNAs,” Nucleic Acid Therapeutics, vol. 23, no. 3, pp. 188–194, 2013. View at Google Scholar
  14. S. Q. Harper, P. D. Staber, X. He et al., “RNA interference improves motor and neuropathological abnormalities in a Huntington's disease mouse model,” Proceedings of the National Academy of Sciences of the United States of America, vol. 102, no. 16, pp. 5820–5825, 2005. View at Publisher · View at Google Scholar · View at Scopus
  15. B. Huang, J. Schiefer, C. Sass, G. B. Landwehrmeyer, C. M. Kosinski, and S. Kochanek, “High-capacity adenoviral vector-mediated reduction of huntingtin aggregate load in vitro and in vivo,” Human Gene Therapy, vol. 18, no. 4, pp. 303–311, 2007. View at Publisher · View at Google Scholar · View at Scopus
  16. Y. Machida, T. Okada, M. Kurosawa, F. Oyama, K. Ozawa, and N. Nukina, “rAAV-mediated shRNA ameliorated neuropathology in Huntington disease model mouse,” Biochemical and Biophysical Research Communications, vol. 343, no. 1, pp. 190–197, 2006. View at Publisher · View at Google Scholar · View at Scopus
  17. G. J. Yohrling IV, G. C.-T. Jiang, M. M. DeJohn et al., “Analysis of cellular, transgenic and human models of Huntington's disease reveals tyrosine hydroxylase alterations and substantia nigra neuropathology,” Molecular Brain Research, vol. 119, no. 1, pp. 28–36, 2003. View at Publisher · View at Google Scholar · View at Scopus
  18. J. M. van Raamsdonk, M. R. Hayden, and B. R. Leavitt, “Experimental models of Huntington's disease,” Drug Discovery Today: Disease Models, vol. 2, no. 4, pp. 291–297, 2005. View at Publisher · View at Google Scholar · View at Scopus
  19. R. J. Ferrante, “Mouse models of Huntington's disease and methodological considerations for therapeutic trials,” Biochimica et Biophysica Acta—Molecular Basis of Disease, vol. 1792, no. 6, pp. 506–520, 2009. View at Publisher · View at Google Scholar · View at Scopus
  20. A. L. Southwell, S. C. Warby, J. B. Carroll et al., “A fully humanized transgenic mouse model of Huntington disease,” Human Molecular Genetics, vol. 22, no. 1, pp. 18–34, 2013. View at Publisher · View at Google Scholar
  21. M. DiFiglia, M. Sena-Esteves, K. Chase et al., “Therapeutic silencing of mutant huntingtin with siRNA attenuates striatal and cortical neuropathology and behavioral deficits,” Proceedings of the National Academy of Sciences of the United States of America, vol. 104, no. 43, pp. 17204–17209, 2007. View at Publisher · View at Google Scholar · View at Scopus